September 2013 – August 2014, Diamyd Medical AB (publ), Fiscal year 2013/2014 Reporting period, June 1, 2014 – August 31, 2014 · Net sales amounted to MSEK 0.2 (0,1) · Loss before tax amounted to MSEK -3.3 (-4.3) · Liquid assets and short term investments amounted to MSEK 35.7 (65.5) as of August 31, 2014 Full year, September 1, 2013 – August 31, 2014 · Net sales amounted to MSEK 0.4 (0.1) · Loss before tax amounted to MSEK -16.0 (-12.6) Significant events during the reporting period · Clinical study with Diamyd Medical’s diabetes vaccine fully recruited · Diamyd Medical reinforces focus on business development · Study with Diamyd Medical’s diabetes vaccine awarded EU-funding Significant events after the reporting period · Diamyd-licensed technology cures diabetes in pre-clinical model · New method to give Diamyd® will be tested in adults with type 1 diabetes · Diamyd Medical and Protein Sciences deepen commitment to develop new treatment for diabetes CEO comments Diamyd Medical has made a flying start to the autumn and the company is a hive of activity. Among all these activities, we will manufacture fresh GAD protein at our long-term partner Protein Sciences Corporation. The GAD protein is the active substance in the diabetes vaccine Diamyd®, which is being developed for the treatment and prevention of autoimmune diabetes. Since a portion of the payment is being made in Diamyd shares, Protein Sciences will become a strategic and one of the largest shareholders in Diamyd Medical. Having a well-established manufacturing process for Diamyd® in place represents a substantial value and further deepening the relationship with Protein Sciences in this manner is very positive for ensuring long-term manufacturing. We are meeting increasing interest for conducting studies with the diabetes vaccine so it is strategically important that we keep the production process updated and, continuously, ensure that GAD protein and ready-for-use Diamyd® are available for clinical trials. Diamyd® is the Antigen-Based Therapy (ABT) that is at the forefront of development and can be used on children due to its favorable safety profile demonstrated in extensive earlier clinical trials. Together with researchers, we strongly believe in attacking the disease process for type 1 diabetes from several angles simultaneously by combining Diamyd® with other drugs and we are preparing such combination trials together with half a dozen different groups. The preparations for several of these have progressed as far as discussions with the regulatory authorities. A new investigator-initiated trial with Diamyd® recently received approval from the Swedish Medical Products Agency and is being launched. In analogy to the development in allergy therapy, where the administration of allergen into lymph nodes significantly improved the efficacy, in this study, a low dose of Diamyd® will be administered directly into lymph nodes in combination with vitamin D treatment. Initially, this exciting concept will be tested on a small group of adult patients recently diagnosed with type 1 diabetes. The entire study will be conducted at Linköping University under Professor Johnny Ludvigsson. Another investigator-initiated combination trial where discussions are ongoing with the US Food and Drug Administration (FDA) pertains to the combination of Diamyd® and gamma amino butyric acid (GABA). Last year, Diamyd Medical secured a license from the University of California, Los Angeles (UCLA) to the exclusive intellectual rights for GABA for the treatment of diabetes, among other conditions. The idea of combining GABA with Antigen-Based Therapy (ABT) for type 1 diabetes gained further support from a scientific paper at the beginning of September. In the paper, scientists at UCLA confirmed previous findings, that combination therapy with GABA and ABT acts synergistically when treating non -obese diabetic (NOD) mice, a model for type 1 diabetes. The new paper concludes that the use of GABA in combination with ABT also has potential for type 1 diabetes intervention in humans. In parallel with the planning of new trials, one of the world’s first combination trials is ongoing in Sweden – DIABGAD-1. Slightly more than 60 children and adolescents with newly diagnosed type 1 diabetes are participating in the trial and testing Diamyd® in a unique combination with vitamin D and ibuprofen. The trial received a nice contribution corresponding to about SEK 1.1 million in EU funding at the end of August. The expectation is to be able to present the results from the first six months of the trial at the start of 2015 with a focus on immunological markers. Later in 2015, the 15-month results should also be available from the trial and these will be able to say more about the effects of the treatment on the patients’ ability to produce their own insulin. Having widened the Company’s focus areas during the fiscal year through investments in the Swedish company Cellaviva, which is establishing a bank for umbilical cord blood and stem cell research, and the US medical technology company Companion Medical, we are now looking to leverage the increasing interest in Diamyd® and investing energy in identifying collaboration partners. Stockholm, October 15, 2014 Peter Zerhouni President and CEO Diamyd Medical AB (publ) Significant events during the reporting period June 1, 2014 – August 31, 2014 Clinical study with Diamyd Medical’s diabetes vaccine fully recruited All participants have been included in a Phase II clinical study, DIABGAD-1, in which Diamyd Medical’s diabetes vaccine Diamyd®, in a unique combination with other drugs, is tested in children and adolescents recently diagnosed with type 1 diabetes. The first results from the researcher-initiated study will thereby be available in the beginning of 2015. Diamyd Medical reinforces focus on business development Diamyd Medical’s lead candidate therapeutic Diamyd® for treatment and prevention of type 1 diabetes experiences an increased interest. Consensus is that the disease must be attacked by inducing tolerance to beta cell auto-antigens at a time when the inflammatory components of the immune system are kept at bay. Diamyd® is the furthest developed beta cell specific auto-antigen (GAD65 formulated in alum) available and the Company is currently in discussion with half a dozen parties about new combination studies. Diamyd Medical is therefore preparing to meet this increased interest by reinforcing its focus on business development. To make available further management resources for this, the Board has asked the Company Chairman, Anders Essen-Möller, to assume responsibility for Diamyd Medical’s external communication, with the aim of meeting the interest from potential partners and other stakeholders. Study with Diamyd Medical’s diabetes vaccine awarded EU-funding The ongoing combination study DIABGAD-1 has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The grant comes from an FP7 project where Linköping University and Diamyd Medical are included. The DIABGAD study aims to evaluate whether vitamin D and ibuprofen act synergistically with the diabetes vaccine Diamyd® in order to preserve the insulin producing capacity in children newly diagnosed with type 1 diabetes. The first results from the study are expected to be presented in the beginning of 2015. Significant events after the reporting period Diamyd-licensed technology cures diabetes in pre-clinical model Researchers at UCLA have confirmed earlier findings that combinations of GABA and Antigen Based Therapy (ABT) works synergistically as a treatment in the NOD mouse model of type 1 diabetes. Diamyd Medical is the exclusive licensee for the commercialization of UCLA’s GABA technology for metabolic diseases including in diabetes. New method to give Diamyd® will be tested in adults with type 1 diabetes A new way to give Diamyd® will be tested in a clinical study with five adults newly diagnosed with type 1 diabetes. The investigator initiated study has been approved by the Swedish MPA. In analogy to the development in allergy therapy, where the administration of allergen into lymph nodes has significantly improved the efficacy, Diamyd® will in this study be administered directly into lymph nodes in combination with treatment with vitamin D. Diamyd Medical and Protein Sciences deepen commitment to develop new treatment for diabetes Protein Sciences has broadened its commitment to diabetes and become a strategic and significant shareholder in Diamyd Medical, its long-time partner in this domain. Protein Sciences will manufacture product for upcoming late stage clinical trials for type 1 diabetes involving Diamyd Medical’s recombinant GAD (glutamic acid decarboxylase) protein made using Protein Sciences’ proprietary Baculovirus Expression Vector System (BEVS) technology. The diabetes vaccine Diamyd® (GAD formulated with alum) has been evaluated as a monotherapy for type 1 diabetes in a Phase III study and data suggests that Diamyd® may be a critical component of combination therapies that pairs the tolerance-inducing GAD antigen with anti-inflammatory agents for the treatment and prevention of type 1 diabetes. This is being evaluated in ongoing and upcoming Phase II studies. *** To read the complete report, please see attached pdf, or visit www.diamyd.com *** For more information please contact: Peter Zerhouni, President and CEO Diamyd Medical AB (publ). Phone: +46 8 661 00 26 Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden Phone: +46 8 661 00 26 Fax: +46 8 661 63 68 E-mail: info@diamyd.com Reg no: 556242-3797 Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company’s operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.
Financial Statement 13/14 September 2013 – August 2014,
Top 10 Most Recent News Articles
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy
Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...
Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today
Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...
Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026
Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...
Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D
Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...
Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools
Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...
Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice
Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...
Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions
A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....
Continue Reading
Concierto's Azure Push Puts Sovereignty on Display
Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....
Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai
Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...
Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves
Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...
Continue ReadingTop 5 Most Recently Viewed Articles
B. Riley Financial Partners with Oaktree to Enhance Services
B. Riley Financial and Oaktree: A Strategic Collaboration B. Riley Financial, Inc. (NASDAQ: RILY) is thrilled to announce a new partnership with Oaktree Capital Management, L.P. to strengthen its Great American Group businesses. Definitive Agreement Signed The companies have finalized a definitive agreement enabling a collaboration through a newly formed holding company...
Continue Reading
General Motors Faces Changes: A Shift in EV Incentive Strategy
General Motors Adjusts EV Incentives General Motors Co. (NYSE: GM) has decided to revise its plans concerning electric vehicle (EV) incentives after initially suggesting options beyond the Federal EV Credit deadline. This shift comes shortly after rising scrutiny from political figures around the implications of such financial strategies. Concerns Raised by Key...
Continue Reading
Pacsun Unveils Stylish New Sunglasses Collection for All
Pacsun Launches an Elegant Sunglass Collection Pacsun has taken a bold step in expanding its product range by introducing a new collection of premium sunglasses. This unisex line represents the brand's commitment to elevating its accessory offerings, appealing to a broader audience of style-conscious consumers. Innovative Designs in Sunglass Fashion With the release of...
Continue Reading
Exploring the Rapid Growth of the Opioid Use Disorder Market
Understanding the Opioid Use Disorder Market and Its Promising Growth The opioid crisis represents a major public health challenge, significantly impacting communities across the globe. According to research, the Opioid Use Disorder Market was evaluated at approximately USD 3.7 billion recently, with an exciting projection to surge to USD 9.02 billion by 2032. This...
Continue Reading
Artea Bankas Secures ECB Approval for Stock Buyback Initiative
Artea Bankas Secures ECB Approval for Stock Buyback Initiative AB Artea Bankas has recently gained essential approval from the European Central Bank (ECB) allowing the bank to buy back up to 4,500,000 of its own shares, marking a significant step in enhancing shareholder value. This buyback program is anticipated to commence within one year, demonstrating the bank's...
Continue Reading